尼拉帕利联合帕博利珠单抗治疗晚期或转移性三阴性乳腺癌的开放标签临床试验
这项开放标签、单臂、2期研究在34个美国中心纳入55例晚期或转移性三阴性乳腺癌患者,给予尼拉帕利200 mg每日一次口服联合帕博利珠单抗200 mg静脉注射(每21天周期第1天)。在47例可评估疗效患者中,客观缓解率为21%(90% CI,12%-33%),疾病控制率为49%(90% CI,36%-62%);肿瘤BRCA突变患者客观缓解率47%(90% CI,24%-70%),BRCA野生型患者11%(90% CI,3%-26%)。联合治疗显示出可控的安全性,最常见的≥3级治疗相关不良事件为贫血(18%)、血小板减少(15%)和疲乏(7%)。
要点
- 尼拉帕利联合帕博利珠单抗在晚期或转移性三阴性乳腺癌中显示 promising 抗肿瘤活性,肿瘤BRCA突变患者缓解率数值更高。
- 可评估疗效人群客观缓解率21%(90% CI,12%-33%),疾病控制率49%(90% CI,36%-62%)。
- 联合治疗安全性可控,常见≥3级治疗相关不良事件为贫血18%、血小板减少15%、疲乏7%。
核心结论
- 尼拉帕利联合帕博利珠单抗在晚期或转移性三阴性乳腺癌患者中提供有前景的抗肿瘤活性,肿瘤BRCA突变者缓解率数值更高。
- 该联合治疗安全性可控,值得进一步研究。
研究设计与样本
- 开放标签、单臂、2期研究,在美国34个中心纳入55例符合条件的晚期或转移性三阴性乳腺癌患者,不论BRCA突变状态或PD-L1表达。
- 数据收集时间为2017年1月3日至2018年10月29日,分析时间为2018年10月29日至2019年2月27日。
- 患者接受尼拉帕利200 mg每日一次口服联合帕博利珠单抗200 mg静脉注射(每21天周期第1天)。
主要发现
- 在55例女性全分析人群中(中位年龄54岁,范围32-90岁),5例确认完全缓解,5例确认部分缓解,13例疾病稳定,24例疾病进展。
- 在47例可评估疗效人群中,客观缓解率包括10例(21%;90% CI,12%-33%),疾病控制率包括23例(49%;90% CI,36%-62%)。
- 数据截止时中位缓解持续时间未达到,分析时7例患者仍在接受治疗。
- 在15例可评估的肿瘤BRCA突变患者中,客观缓解率包括7例(47%;90% CI,24%-70%),疾病控制率包括12例(80%;90% CI,56%-94%),中位无进展生存期为8.3个月(95% CI,2.1个月至不可估计)。
- 在27例可评估的BRCA野生型肿瘤患者中,客观缓解率包括3例(11%;90% CI,3%-26%),疾病控制率包括9例(33%;90% CI,19%-51%),中位无进展生存期为2.1个月(95% CI,1.4-2.5个月)。
关键数值与推荐
- 主要终点为按实体瘤疗效评价标准1.1版评估的客观缓解率。
- 次要终点为安全性、疾病控制率(完全缓解加部分缓解加疾病稳定)、缓解持续时间、无进展生存期和总生存期。
- 最常见的≥3级治疗相关不良事件为贫血(10例[18%])、血小板减少(8例[15%])和疲乏(4例[7%])。
- 免疫相关不良事件报告于8例患者(15%),其中2例(4%)为3级;未检测到新的安全性信号。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti-programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the clinical activity (primary) and safety (secondary) of combination treatment with niraparib and pembrolizumab in patients with advanced or metastatic TNBC. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-arm, phase 2 study enrolled 55 eligible patients with advanced or metastatic TNBC irrespective of BRCA mutation status or programmed death-ligand 1 (PD-L1) expression at 34 US sites. Data were collected from January 3, 2017, through October 29, 2018, and analyzed from October 29, 2018, through February 27, 2019. INTERVENTIONS: Patients were administered 200 mg of oral niraparib once daily in combination with 200 mg of intravenous pembrolizumab on day 1 of each 21-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate (ORR) per the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points were safety, disease control rate (DCR; complete response plus partial response plus stable disease), duration of response (DOR), progression-free survival (PFS), and overall survival. RESULTS: Within the full study population of 55 women (median age, 54 years [range, 32-90 years]), 5 patients had confirmed complete responses, 5 had confirmed partial responses, 13 had stable disease, and 24 had progressive disease. In the efficacy-evaluable population (n = 47), ORR included 10 patients (21%; 90% CI, 12%-33%) and DCR included 23 (49%; 90% CI, 36%-62%). Median DOR was not reached at the time of the data cutoff, with 7 patients still receiving treatment at the time of analysis. In 15 evaluable patients with tumor BRCA mutations, ORR included 7 patients(47%; 90% CI, 24%-70%), DCR included 12 (80%; 90% CI, 56%-94%), and median PFS was 8.3 months (95% CI, 2.1 months to not estimable). In 27 evaluable patients with BRCA wild-type tumors, ORR included 3 patients (11%; 90% CI, 3%-26%), DCR included 9 (33%; 90% CI, 19%-51%), and median PFS was 2.1 months (95% CI, 1.4-2.5 months). The most common treatment-related adverse events of grade 3 or higher were anemia (10 [18%]), thrombocytopenia (8 [15%]), and fatigue (4 [7%]). Immune-related adverse events were reported in 8 patients (15%) and were grade 3 in 2 patients (4%); no new safety signals were detected. CONCLUSIONS AND RELEVANCE: Combination niraparib plus pembrolizumab provides promising antitumor activity in patients with advanced or metastatic TNBC, with numerically higher response rates in those with tumor BRCA mutations. The combination therapy was safe with a tolerable safety profile, warranting further investigation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02657889.
引用
- Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol. 2019. PMID: 31194225. doi:10.1001/jamaoncol.2019.1029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。